At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 229 enrolled
Drug / intervention
valsartan +1 moredrug
Likely dose
valsartan 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Prospective, Randomized, Open-label Study With Blinded Outcome Evaluation to Evaluate the Effects of Systolic Blood Pressure Lowering to Different Targets (Less Than 130 mmHg vs. Less Than 140 mmHg) on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction
In Brief
A Phase 4 clinical trial evaluating valsartan and amlodipine for Hypertension and Diastolic Dysfunction. Completed, enrolled 229 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the effects of treatment with valsartan + amlodipine to a target systolic blood pressure (SBP)\<130 mmHg compared to the Joint National Commission on the Treatment of Hypertension 7 recommended target SBP of \<140 mmHg on the intrinsic diastolic properties of the myocardium in patients with hypertension and echocardiographic evidence of diastolic dysfunction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension, Diastolic Dysfunction
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2006
First PostedAug 2007
Primary CompletionJan 2008
TodayJul 2026
First PostedAug 31, 2007
Enrollment StartNov 1, 2006
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 18.8 years ago
Interventions
valsartandrug
160 mg or 320 mg tablets once a day
amlodipinedrug
5 mg or 10 mg tablets once a day